An Anti-CD19/CTLA-4 Switch Improves Efficacy and Selectivity of CAR T Cells Targeting CD80/86-Upregulated DLBCL

Researchers reported that allogeneic transplantation of genetically engineered, primary, hypoimmune, pseudo-islets resulted in their engraftment into a fully immunocompetent, diabetic non-human primate wherein they provide stable endocrine function and enable insulin independence without inducing any detectable immune response in the absence of immunosuppression.
[Cell Reports Medicine]
Full Article